Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy

Biomark Med. 2011 Oct;5(5):645-7. doi: 10.2217/bmm.11.64.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / pathology
  • Alzheimer Disease / therapy
  • Amyloid beta-Peptides / metabolism
  • Biomarkers / metabolism
  • Cholecalciferol / therapeutic use
  • Curcumin / analogs & derivatives
  • Curcumin / therapeutic use
  • Diarylheptanoids
  • Disease Progression
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • N-Acetylglucosaminyltransferases / genetics
  • N-Acetylglucosaminyltransferases / metabolism*
  • Phagocytosis
  • Precision Medicine
  • Prognosis

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Diarylheptanoids
  • Cholecalciferol
  • bisdemethoxycurcumin
  • N-Acetylglucosaminyltransferases
  • beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase
  • Curcumin